Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:21628.

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Dongxu Pei, Yongwei Li _, Xinwei Liu, Sha Yan, Xiaolan Guo, Xiaona Xu and Xiaoxia Guo

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:13030-13038. https://doi.org/10.18632/oncotarget.14712

Metrics: PDF 1730 views  |   HTML 1857 views  |   ?  


Dongxu Pei1, Yongwei Li1, Xinwei Liu1, Sha Yan1, Xiaolan Guo1, Xiaona Xu1, Xiaoxia Guo2

1Department of Clinical Laboratory, Henan Province Hospital of TCM, Zhengzhou, Henan, China

2Department of Clinical Laboratory, Anyang Hospital of Traditional Chinese Medicine

Correspondence to:

Yongwei Li, email: [email protected]

Keywords: fibulin-3, malignant pleural mesothelioma, diagnosis, prognosis, biomarker

Received: September 26, 2016     Accepted: January 08, 2017     Published: January 18, 2017


Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. Results manifested that humoral fibulin-3 sustained a pooled sensitivity of 0.62 (95% CI: 0.45–0.77) and specificity of 0.82 (95% CI: 0.73–0.89) in discriminating MPM patients from cancer-free individuals, corresponding to an AUC (area under the curve) of 0.81. For the survival analysis, fibulin-3 expression was not markedly associated with overall survival (OS) time of the MPM patients [HR (hazard ratio): 1.84, 95% CI: 0.75–4.56, P = 0.185]. In the subgroup analyses stratified by test matrix and ethnicity, data revealed that serum-based fibulin-3 examination achieved superior accuracy than plasma-based analysis (sensitivity: 0.77 versus 0.54; specificity: 0.85 versus 0.77; AUC: 0.92 versus 0.69); additionally, testing of fibulin-3 in Europeans retained higher efficacy than those in Americans and Australians. Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14712